These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23248394)

  • 21. Therapeutic effects of multifunctional tetramethylpyrazine nitrone on models of Parkinson's disease in vitro and in vivo.
    Guo B; Xu D; Duan H; Du J; Zhang Z; Lee SM; Wang Y
    Biol Pharm Bull; 2014; 37(2):274-85. PubMed ID: 24305623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
    Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
    Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term supplementation with plant extracts rich in flavonoids protect nigrostriatal dopaminergic neurons in a rat model of Parkinson's disease.
    Datla KP; Zbarsky V; Rai D; Parkar S; Osakabe N; Aruoma OI; Dexter DT
    J Am Coll Nutr; 2007 Aug; 26(4):341-9. PubMed ID: 17906186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vasoactive intestinal peptide (VIP) treatment of Parkinsonian rats increases thalamic gamma-aminobutyric acid (GABA) levels and alters the release of nerve growth factor (NGF) by mast cells.
    Korkmaz OT; Tunçel N; Tunçel M; Oncü EM; Sahintürk V; Celik M
    J Mol Neurosci; 2010 Jun; 41(2):278-87. PubMed ID: 19953344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methylparaben protects 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells and improved behavioral impairments in mouse model of Parkinson's disease.
    Kopalli SR; Noh SJ; Koppula S; Suh YH
    Neurotoxicology; 2013 Jan; 34():25-32. PubMed ID: 23068419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease.
    Khan MM; Ahmad A; Ishrat T; Khan MB; Hoda MN; Khuwaja G; Raza SS; Khan A; Javed H; Vaibhav K; Islam F
    Brain Res; 2010 Apr; 1328():139-51. PubMed ID: 20167206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroprotective effects of Withania somnifera on 6-hydroxydopamine induced Parkinsonism in rats.
    Ahmad M; Saleem S; Ahmad AS; Ansari MA; Yousuf S; Hoda MN; Islam F
    Hum Exp Toxicol; 2005 Mar; 24(3):137-47. PubMed ID: 15901053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
    Youdim MB; Stephenson G; Ben Shachar D
    Ann N Y Acad Sci; 2004 Mar; 1012():306-25. PubMed ID: 15105275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serofendic acid prevents 6-hydroxydopamine-induced nigral neurodegeneration and drug-induced rotational asymmetry in hemi-parkinsonian rats.
    Inden M; Kitamura Y; Kondo J; Hayashi K; Yanagida T; Takata K; Tsuchiya D; Yanagisawa D; Nishimura K; Taniguchi T; Shimohama S; Sugimoto H; Akaike A
    J Neurochem; 2005 Nov; 95(4):950-61. PubMed ID: 16135081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Moutan Cortex Radicis inhibits the nigrostriatal damage in a 6-OHDA-induced Parkinson's disease model.
    Choi YG; Hong YM; Kim LH; Yeo S; Lim S
    Chin J Nat Med; 2018 Jul; 16(7):490-498. PubMed ID: 30080647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease.
    Zhang S; Wang XJ; Tian LP; Pan J; Lu GQ; Zhang YJ; Ding JQ; Chen SD
    J Neuroinflammation; 2011 Nov; 8():154. PubMed ID: 22053982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
    Liu H; Jia L; Chen X; Shi L; Xie J
    Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The significance of rotational behavior and sensitivity of striatal dopamine receptors in hemiparkinsonian rats: A comparative study of lactacystin and 6-OHDA.
    Konieczny J; Czarnecka A; Lenda T; Kamińska K; Antkiewicz-Michaluk L
    Neuroscience; 2017 Jan; 340():308-318. PubMed ID: 27826109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats.
    Srinivasan J; Schmidt WJ
    Eur J Neurosci; 2003 Jun; 17(12):2586-92. PubMed ID: 12823465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism of the beneficial effect of melatonin in experimental Parkinson's disease.
    Yildirim FB; Ozsoy O; Tanriover G; Kaya Y; Ogut E; Gemici B; Dilmac S; Ozkan A; Agar A; Aslan M
    Neurochem Int; 2014 Dec; 79():1-11. PubMed ID: 25263280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson's disease by enhancing Nrf2 activity.
    Jing X; Shi H; Zhang C; Ren M; Han M; Wei X; Zhang X; Lou H
    Neuroscience; 2015 Feb; 286():131-40. PubMed ID: 25449120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Shin KS; Choi HS; Zhao TT; Suh KH; Kwon IH; Choi SO; Lee MK
    Arch Pharm Res; 2013 Jun; 36(6):759-67. PubMed ID: 23539311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. JM-20 protects against 6-hydroxydopamine-induced neurotoxicity in models of Parkinson's disease: Mitochondrial protection and antioxidant properties.
    Fonseca-Fonseca LA; da Silva VDA; Wong-Guerra M; Ramírez-Sánchez J; Yaquis ASP; Ochoa-Rodríguez E; Verdecia-Reyes Y; de Araújo FM; Santana RC; Outeiro TF; Costa SL; Núñez-Figueredo Y
    Neurotoxicology; 2021 Jan; 82():89-98. PubMed ID: 33232743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats.
    Jin F; Wu Q; Lu YF; Gong QH; Shi JS
    Eur J Pharmacol; 2008 Dec; 600(1-3):78-82. PubMed ID: 18940189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuroprotection by crocetin in a hemi-parkinsonian rat model.
    Ahmad AS; Ansari MA; Ahmad M; Saleem S; Yousuf S; Hoda MN; Islam F
    Pharmacol Biochem Behav; 2005 Aug; 81(4):805-13. PubMed ID: 16005057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.